Table IV.

Adjusted^a and weighted^b mean proportion of cycles (95% CI) resulting in implantation, clinical pregnancy and live birth in association with urinary oxidative stress biomarkers among 246 men with partners undergoing 468 IVF and IUI cycles.

	Implantation	p-valuec	Clinical pregnancy	p-valuec	Live birth	p-valuec
8-iso-PGF  2α
T1 lower	0.51 (0.40, 0.61)	0.90	0.46 (0.37, 0.57)	0.77	0.42 (0.33, 0.53)	0.18
T2 middle	0.50 (0.39, 0.60)		0.44 (0.34, 0.55)		0.33 (0.24, 0.44)
T3 upper	0.46 (0.36, 0.57)	0.64	0.40 (0.31, 0.51)	0.60	0.31 (0.22, 0.41)	0.81
F  2  -IsoP-M
T1 lower	0.49 (0.39, 0.58)	0.68	0.43 (0.34, 0.52)	0.51	0.40 (0.31, 0.49)	0.60
T2 middle	0.52 (0.42, 0.62)		0.47 (0.38, 0.57)		0.36 (0.27, 0.46)
T3 upper	0.46 (0.35, 0.57)	0.45	0.41 (0.31, 0.52)	0.39	0.31 (0.21, 0.42)	0.45

^aAdjusted for paternal age (continuous), paternal BMI (continuous), smoking (never vs. ever), primary infertility diagnosis (male, female, unexplained), race (white vs. other) and type of procedure (IVF vs. IUI).

^bModels were weighted to account for number of cycles with weights assigned using inverse number of cycles.

^c  P-value represents differences compared to the 2^nd tertile.

Note: There were 2 cycles missing information on age, BMI, smoking and race (1 man). There were 2 cycles missing information on F₂-IsoP-M (2 men).

Abbreviations: 8-isoprostane-PGF_2α (8-iso-PGF_2α); 8-isoprostane-PGF_2α metabolite (F₂-isoP-M); in-vitro fertilisation (IVF); intrauterine insemination (IUI).